Citius Pharmaceuticals (CTXR) Net Equity Issued and Repurchased (2011 - 2026)
Citius Pharmaceuticals' (CTXR) quarterly Net Equity Issued and Repurchased came in at -$62764.0 in Q1 2026, down 101.81% YoY from $3.5 million in Q1 2025, and down 100.3% on a QoQ basis from $20.9 million in Q4 2025.
Citius Pharmaceuticals (CTXR) Net Equity Issued and Repurchased (2011 - 2026) Analysis & Trends
Citius Pharmaceuticals (CTXR) has 6 years of Net Equity Issued and Repurchased data on file, last reported at -$62764.0 in Q1 2026.
- Quarterly Net Equity Issued and Repurchased fell 101.81% year-over-year to -$62764.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $47.1 million (up 668.68% YoY) and the FY2025 annual result came in at $32.3 million, up 134.02% from the prior year.
- Net Equity Issued and Repurchased fell to -$62764.0 in Q1 2026, from $20.9 million in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $20.9 million in Q4 2025 to a low of -$62764.0 in Q1 2026.
- A 3-year average of $7.6 million and a median of $3.5 million in 2025 frame the typical range for Net Equity Issued and Repurchased.
- Annual changes were most pronounced in 2025 — Net Equity Issued and Repurchased jumped 18539.67% — and 2026, when it tumbled 101.81%.
- Tracing CTXR's Net Equity Issued and Repurchased over 3 years: stood at $2.6 million in 2024, then jumped by 711.09% to $20.9 million in 2025, then sank by 100.3% to -$62764.0 in 2026.
- The last three Net Equity Issued and Repurchased figures came in at -$62764.0 (Q1 2026), $20.9 million (Q4 2025), and $15.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Citius Pharmaceuticals | 15.71 Mn | 15.71 Mn | 1.00 Mn | 4.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -62,764.00 |
| Mar 31, 2026 | -62,764.00 |
| Dec 31, 2025 | 20.88 Mn |
| Dec 31, 2025 | 20.88 Mn |
| Sep 30, 2025 | 15.79 Mn |
| Sep 30, 2025 | 15.79 Mn |
| Jun 30, 2025 | 10.47 Mn |
| Jun 30, 2025 | 10.47 Mn |
| Mar 31, 2025 | 3.47 Mn |
| Mar 31, 2025 | 3.47 Mn |
| Dec 31, 2024 | 2.57 Mn |
| Dec 31, 2024 | 2.57 Mn |
| Sep 30, 2024 | 84,733.00 |
| Sep 30, 2024 | 84,733.00 |
| Dec 31, 2020 | 500.00 |
| Dec 31, 2020 | 500.00 |
| Sep 30, 2014 | 50,000.00 |
| Sep 30, 2014 | 50,000.00 |
| Jun 30, 2014 | 50,000.00 |
| Jun 30, 2014 | 50,000.00 |